Enanta Pharmaceuticals
ENTA
153 hedge funds and large institutions have $418M invested in Enanta Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 69 increasing their positions, 32 reducing their positions, and 13 closing their positions.
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
116% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 32
12% more funds holding
Funds holding: 137 → 153 (+16)
13% less capital invested
Capital invested by funds: $483M → $418M (-$64.9M)
19% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $2M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.69M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$4.87M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$2.47M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.45M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$16.1M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.1M |
| 3 |
O
OrbiMed
New York
|
-$7.1M |
| 4 |
MVM
McClain Value Management
New Canaan,
Connecticut
|
-$4.14M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$3.65M |
ENTA Hedge Fund Activity: Q1 2016 in Review
153 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2016, worth a combined $418M — down 13% from $483M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ENTA positions and 13 closed out — a net gain of 18 holders — while 69 added to existing stakes and 32 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $6.69M. The largest seller was Invesco, cutting an estimated $16.1M.
- 153 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2016, up from 137 in Q4 2015.
- Funds reported $418M of Enanta Pharmaceuticals stock for Q1 2016, down 13% quarter-over-quarter.
- 31 funds opened new Enanta Pharmaceuticals positions in Q1 2016 and 13 closed out, a net change of +18 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2016 was EcoR1 Capital, an estimated $6.69M added.
- The largest Enanta Pharmaceuticals seller in Q1 2016 was Invesco, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2016.